Compare IDEXX Laboratories, Inc. (IDXX) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while JPMorgan Ultra Short Income ETF trades at $50.3 (market cap $42.37B). The key difference: IDEXX Laboratories, Inc. and JPMorgan Ultra Short Income ETF are close in size by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 7,889,185). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and JPMorgan Ultra Short Income ETF for 47 Days on average.
| IDXX | JPST | |
|---|---|---|
Market Cap | $40.43B | $42.37B |
Volume | 692,164 | 7,889,185 |
Sector | Health | Fixed Income |
52-Week High | $766.68 | $50.78 |
52-Week Low | $504.70 | $50.22 |
Typical Hold Time | 46 Days | 47 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
JPST trades at $50.27 with no recent price movement, showing stability amid bearish technical signals from moving averages. The ETF maintains consistent dividend distributions of $0.17 monthly, positioning as a cash-equivalent alternative. Recent news highlights institutional position adjustments and growing investor interest in ultra-short income strategies as rates rise.
The outlook remains stable for income-focused investors seeking minimal volatility. Key risks include interest rate sensitivity and active management performance versus peers. Recent institutional selling activity suggests some profit-taking despite the fund's role in portfolio cash management strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
